Clinicopathological Features of Gastric Cancer in a Cohort of Gulf Council Countries’ Patients: A Cross Sectional Study of 96 Cases

Authors

  • Humaid O Al-Shamsi Department of Oncology–Burjeel Cancer Institute–Burjeel Medical City, Abu Dhabi, United Arab Emirates Author
  • Mehdi Afrit Emirates Oncology Society, Dubai, United Arab Emirates Author
  • Ibrahim Abu-Gheida Emirates Oncology Society, Dubai, United Arab Emirates Author
  • Faryal Iqbal Innovation and Research Center–Burjeel Cancer Institute–Burjeel Medical City, Abu Dhabi, United Arab Emirates Author
  • Sadir Alrawi Innovation and Research Center–Burjeel Cancer Institute–Burjeel Medical City, Abu Dhabi, United Arab Emirates Author
  • Jaffer A Ajani Department of Gastrointestinal Medical Oncology; The University of Texas MD Anderson Cancer Center, Houston, Texas, US Author

DOI:

https://doi.org/10.47363/JONRR/2021(2)134

Keywords:

Clinicopathological, Gastric Cancer

Abstract

Objective: This retrospective work aims to report the epidemiologic and clinicopathological features of Gulf Cooperation Council (GCC) patients with Gastric Cancer (GC).

Patients and Methods: This retrospective study evaluated patients from GCC countries presenting with GC, treated at the MD Anderson cancer, University of Texas , Houston , Texas from 1981 to 2015. after obtaining an Institutional Review Board approval to conduct this retrospective study the data were collected from the charts of 96 consecutive GCC patients diagnosed with GC electronic and paper medical records (for cases prior to the implementation of the electronic medical records): The charts were reviewed for demographic data, clinical data, diagnostic tools, endoscopic location of the tumour and clinicopathological features of the GC. Statistical analyses were performed by using SPSS version 20. Numerical data were presented as mean +/- standard deviation (SD) (For normally distributed data); median and range (For not normally distributed data). Nominal data were expressed by percentages.

Results: 96 patients identified with histologically confirmed gastric carcinoma from the, from KSA (40%) , UAE (26%) , Qatar (16%) Kuwait (10%), Oman (3%) and Bahrain (2%) of cases. They have a median age of 54.5 years and 40 patients (42%) were aged less than 50 years and a sex-ratio of 1.7(male 61%, female 39%). Intestinal type was the most common histological type in 61% of cases, 30% had signet cell histology and 20.1% (6 out of 28 cases tested) had HER-2 amplification. 76% of the patients presented with stage IV metastatic.

Conclusion: GC in patients from GCC countries is diagnosed at a 10 years earlier age than in Western population. Intestinal‐type histology is the most common similar to the western population and HER-2 amplification rate is similar to Western populations. Most of the cases are metastatic.

Author Biographies

  • Humaid O Al-Shamsi, Department of Oncology–Burjeel Cancer Institute–Burjeel Medical City, Abu Dhabi, United Arab Emirates

    Department of Oncology–Burjeel Cancer Institute–Burjeel Medical City, Abu Dhabi, United Arab Emirates

  • Mehdi Afrit, Emirates Oncology Society, Dubai, United Arab Emirates


    Emirates Oncology Society, Dubai, United Arab Emirates

  • Ibrahim Abu-Gheida, Emirates Oncology Society, Dubai, United Arab Emirates

    Emirates Oncology Society, Dubai, United Arab Emirates

  • Faryal Iqbal, Innovation and Research Center–Burjeel Cancer Institute–Burjeel Medical City, Abu Dhabi, United Arab Emirates


    Innovation and Research Center–Burjeel Cancer Institute–Burjeel Medical City, Abu Dhabi, United Arab Emirates

  • Sadir Alrawi, Innovation and Research Center–Burjeel Cancer Institute–Burjeel Medical City, Abu Dhabi, United Arab Emirates

    Innovation and Research Center–Burjeel Cancer Institute–Burjeel Medical City, Abu Dhabi, United Arab Emirates

  • Jaffer A Ajani, Department of Gastrointestinal Medical Oncology; The University of Texas MD Anderson Cancer Center, Houston, Texas, US


    Department of Gastrointestinal Medical Oncology; The University of Texas MD Anderson Cancer Center, Houston, Texas, US

Downloads

Published

2021-05-10